105 related articles for article (PubMed ID: 32888648)
1. Beneficial effect of erlotinib and trastuzumab emtansine combination in lung tumors harboring EGFR mutations.
Kayatani H; Ohashi K; Ninomiya K; Makimoto G; Nishii K; Higo H; Watanabe H; Kano H; Kato Y; Ninomiya T; Kubo T; Rai K; Ichihara E; Hotta K; Tabata M; Maeda Y; Kiura K
Biochem Biophys Res Commun; 2020 Nov; 532(3):341-346. PubMed ID: 32888648
[TBL] [Abstract][Full Text] [Related]
2. The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer.
Smith DL; Acquaviva J; Sequeira M; Jimenez JP; Zhang C; Sang J; Bates RC; Proia DA
Target Oncol; 2015 Jun; 10(2):235-45. PubMed ID: 25077897
[TBL] [Abstract][Full Text] [Related]
3. Enhanced anti-angiogenic effect of E7820 in combination with erlotinib in epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small-cell lung cancer xenograft models.
Ito K; Semba T; Uenaka T; Wakabayashi T; Asada M; Funahashi Y
Cancer Sci; 2014 Aug; 105(8):1023-31. PubMed ID: 24841832
[TBL] [Abstract][Full Text] [Related]
4. Synergy of EGFR and AURKA Inhibitors in KRAS-mutated Non-small Cell Lung Cancers.
Bagnyukova T; Egleston BL; Pavlov VA; Serebriiskii IG; Golemis EA; Borghaei H
Cancer Res Commun; 2024 May; 4(5):1227-1239. PubMed ID: 38639476
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of a dual epidermal growth factor receptor and ErbB2 kinase inhibitor MP-412 (AV-412) in mouse xenograft models.
Suzuki T; Fujii A; Ohya J; Nakamura H; Fujita F; Koike M; Fujita M
Cancer Sci; 2009 Aug; 100(8):1526-31. PubMed ID: 19459856
[TBL] [Abstract][Full Text] [Related]
6. Pyrotinib combined with thalidomide in advanced non-small-cell lung cancer patients harboring HER2 exon 20 insertions (PRIDE): protocol of an open-label, single-arm phase II trial.
Ai X; Song Z; Jian H; Zhou Z; Chen Z; Yu Y; Li Z; Lu S
BMC Cancer; 2021 Sep; 21(1):1033. PubMed ID: 34530760
[TBL] [Abstract][Full Text] [Related]
7. SOX2 expression is an early event in a murine model of EGFR mutant lung cancer and promotes proliferation of a subset of EGFR mutant lung adenocarcinoma cell lines.
Dogan I; Kawabata S; Bergbower E; Gills JJ; Ekmekci A; Wilson W; Rudin CM; Dennis PA
Lung Cancer; 2014 Jul; 85(1):1-6. PubMed ID: 24746758
[TBL] [Abstract][Full Text] [Related]
8. Endothelin-1-Mediated Drug Resistance in
Pulido I; Ollosi S; Aparisi S; Becker JH; Aliena-Valero A; Benet M; Rodríguez ML; López A; Tamayo-Torres E; Chuliá-Peris L; García-Cañaveras JC; Soucheray M; Dalheim AV; Salom JB; Qiu W; Kaja S; Fernández-Coronado JA; Alandes S; Alcácer J; Al-Shahrour F; Borgia JA; Juan O; Nishimura MI; Lahoz A; Carretero J; Shimamura T
Cancer Res; 2020 Oct; 80(19):4224-4232. PubMed ID: 32747363
[TBL] [Abstract][Full Text] [Related]
9. Real-World Patterns of EGFR Testing and Treatment with Erlotinib for Non-Small Cell Lung Cancer in the United States.
Enewold L; Thomas A
PLoS One; 2016; 11(6):e0156728. PubMed ID: 27294665
[TBL] [Abstract][Full Text] [Related]
10. De novo pulmonary small cell carcinomas and large cell neuroendocrine carcinomas harboring EGFR mutations: Lack of response to EGFR inhibitors.
Le X; Desai NV; Majid A; Karp RS; Huberman MS; Rangachari D; Kent MS; Gangadharan SP; Folch E; VanderLaan PA; Costa DB
Lung Cancer; 2015 Apr; 88(1):70-3. PubMed ID: 25700797
[TBL] [Abstract][Full Text] [Related]
11. Mass spectrometry mapping of epidermal growth factor receptor phosphorylation related to oncogenic mutations and tyrosine kinase inhibitor sensitivity.
Zhang G; Fang B; Liu RZ; Lin H; Kinose F; Bai Y; Oguz U; Remily-Wood ER; Li J; Altiok S; Eschrich S; Koomen J; Haura EB
J Proteome Res; 2011 Jan; 10(1):305-19. PubMed ID: 21080693
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and Therapeutic Targeting of High-Level ERBB2 Amplification in NSCLC.
Odintsov I; Makarem M; Nishino M; Bachert SE; Zhang T; LoPiccolo J; Paweletz CP; Gokhale PC; Ivanova E; Saldanha A; Rudin CM; Lockwood WW; Ladanyi M; Somwar R; Jänne PA; Sholl LM
J Thorac Oncol; 2024 May; 19(5):732-748. PubMed ID: 38154514
[TBL] [Abstract][Full Text] [Related]
13. Monolayer culture alters EGFR inhibitor response through abrogation of microRNA-mediated feedback regulation.
Florio A; Johnson S; Salvatori R; Vasmatzis G
Sci Rep; 2024 Mar; 14(1):7303. PubMed ID: 38538642
[TBL] [Abstract][Full Text] [Related]
14. Use of translational modeling and simulation for quantitative comparison of PF-06804103, a new generation HER2 ADC, with Trastuzumab-DM1.
Betts A; Clark T; Jasper P; Tolsma J; van der Graaf PH; Graziani EI; Rosfjord E; Sung M; Ma D; Barletta F
J Pharmacokinet Pharmacodyn; 2020 Oct; 47(5):513-526. PubMed ID: 32710210
[TBL] [Abstract][Full Text] [Related]
15. EHMT2-mediated transcriptional reprogramming drives neuroendocrine transformation in non-small cell lung cancer.
Yang C; Ma S; Zhang J; Han Y; Wan L; Zhou W; Dong X; Yang W; Chen Y; Gao L; Cui W; Jia L; Yang J; Wu C; Wang Q; Wang L
Proc Natl Acad Sci U S A; 2024 Jun; 121(23):e2317790121. PubMed ID: 38814866
[TBL] [Abstract][Full Text] [Related]
16. Discovery of a Highly Potent and Broadly Effective Epidermal Growth Factor Receptor and HER2 Exon 20 Insertion Mutant Inhibitor.
Jang J; Son J; Park E; Kosaka T; Saxon JA; De Clercq DJH; Choi HG; Tanizaki J; Eck MJ; Jänne PA; Gray NS
Angew Chem Int Ed Engl; 2018 Sep; 57(36):11629-11633. PubMed ID: 29978938
[TBL] [Abstract][Full Text] [Related]
17. Combination Therapy with EGFR Tyrosine Kinase Inhibitors and TEAD Inhibitor Increases Tumor Suppression Effects in EGFR Mutation-positive Lung Cancer.
Ogimoto T; Ozasa H; Tsuji T; Funazo T; Yamazoe M; Hashimoto K; Yoshida H; Hosoya K; Ajimizu H; Nomizo T; Yoshida H; Hamaji M; Menju T; Yoshizawa A; Date H; Hirai T
Mol Cancer Ther; 2024 Apr; 23(4):564-576. PubMed ID: 38052760
[TBL] [Abstract][Full Text] [Related]
18.
Pool M; Terwisscha van Scheltinga AGT; Kol A; Giesen D; de Vries EGE; Lub-de Hooge MN
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1328-1336. PubMed ID: 28315949
[TBL] [Abstract][Full Text] [Related]
19. Quantitative modeling of tumor dynamics and development of drug resistance in non-small cell lung cancer patients treated with erlotinib.
Yin A; Veerman GDM; van Hasselt JGC; Steendam CMJ; Dubbink HJ; Guchelaar HJ; Friberg LE; Dingemans AC; Mathijssen RHJ; Moes DJAR
CPT Pharmacometrics Syst Pharmacol; 2024 Apr; 13(4):612-623. PubMed ID: 38375997
[TBL] [Abstract][Full Text] [Related]
20. In- and ex-vivo molecular imaging of apoptosis to assess sensitivity of non-small cell lung cancer to EGFR inhibitors using probe-based confocal laser endomicroscopy.
Guisier F; Bohn P; Patout M; Piton N; Farah I; Vera P; Thiberville L; Salaün M
PLoS One; 2017; 12(7):e0180576. PubMed ID: 28671975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
